0000950170-24-025900.txt : 20240305 0000950170-24-025900.hdr.sgml : 20240305 20240305161012 ACCESSION NUMBER: 0000950170-24-025900 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEONARD JOHN M CENTRAL INDEX KEY: 0001563584 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 24720411 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS INC STREET 2: 40 ERIE STREET, SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: LEONARD JOHN M. DATE OF NAME CHANGE: 20121204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-03-01 0001652130 Intellia Therapeutics, Inc. NTLA 0001563584 LEONARD JOHN M C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 true true false false President and CEO false Common Stock 2024-03-01 4 A false 113586 0 A 960072 D Common Stock 58415 I By Trust Stock Option (right to buy) 32.66 2024-03-01 4 A false 163929 0 A 2034-02-28 Common Stock 163929 163929 D Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Shares held by the John M. Leonard 2015 Irrevocable Trust. This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. James Basta, attorney-in-fact 2024-03-05